Retinal Diseases Clinical Trial
Official title:
A Prospective Study to Evaluate Swept-Source OCT and Adaptive Optics Imaging of Diseases of the Vitreous, Retina and Choroid
The objectives of this study include using the new technology of SS-OCT (swept source optical coherence tomography) to evaluate morphological abnormalities of the vitreous, retina and choroid and to assess the repeatability of retinal and choroidal thickness measurements in retinal disease using SS-OCT. A secondary objective is to use the new imaging modality of adaptive optics to directly visualize photoreceptor mosaics and microvasculature in eyes with retinal and choroidal disease.
Diseases affecting the vitreous, retina and choroid are among the commonest causes of
sight-loss and vision impairment in England and Wales.
These diseases may display a wide range of pathological features including vitreous, retinal
and subretinal haemorrhage; macular fluid; choroidal inflammation and choroidal masses.
The retina is a 'window to the brain' and there is increasing evidence that neurodegenerative
disorders such as Multiple Sclerosis, Parkinsons Disease and Alzheimers Disease have retinal
manifestations which may have prognostic implications, afford earlier diagnosis, and
potentially act as surrogate endpoints for treatment trials.
In 2012, a further advance in OCT technology was brought to market with the arrival of the
first commercial available swept-source OCT (SS-OCT) device (the Topcon DRI OCT). SS-OCT
technology uses a tuneable laser light source with a longer wavelength of light (typically
1040-1050 nm central wavelength) than the light sources seen in more conventional SD-OCT
devices. This leads to greater tissue penetration with less backscatter from the RPE,
producing images of the choroid with greater resolution with fast image acquisition speeds
(100,000 A scans/s) and longer line scan lengths. The ability to take rapid scans with the
only commercially available SS-OCT device (the DRI, Tocon Inc. Paramus, NY, USA) also
enhances image quality by line scan averaging capability.
The high axial resolution of OCT allows discrimination of the distinct retinal layers that
are affected differentially in different diseases. More direct visualisation of the
photoreceptor layer is afforded by use of an Adaptive Optics Scanning Light Ophthalmoscope
(AOSLO), which provides excellent lateral resolution and allows direct visualisation of the
cone and rod photoreceptor mosaics in vivo by correcting for ocular aberrations and resulting
in a lateral comparable with histopathological sections.
In this study AO images will be correlated with SD- and SS-OCT and used to comprehensively
assess the integrity of the photoreceptor mosaic. Furthermore AO and OCT will be used to
measure nerve fibre layer loss and optic disc changes if relevant to the disease.
The imaging modalities used in this study will be spectral domain optical coherence
topography (SD-OCT), swept source optical coherence tomography (SS-OCT), and adaptive optics
scanning light ophthalmoscope (AOSLO)
The study will examine 300 patients (up to 600 eyes) in a single visit with a further
Adaptive Optics (AO) imaging taken in a subset of patients (up to 200).
Patients in whom AO imaging was possible from a technical perspective will be invited back
for further imaging after 6-12 months (at a standard NHS follow up visit) to probe
longitudinal changes.
An examiner will scan the participants study eye(s) on the same day on each of the 3 imaging
modalities SD-OCT, SS-OCT and AOSLO.
Finally a questionnaire will be used to explore whether participants preferred one OCT
imaging modality over the other (SS-OCT vs SD-OCT).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04968756 -
Evaluating the Safety of the SPECTRALIS CENTAURUS Device
|
N/A | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00437593 -
UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue
|
N/A | |
Completed |
NCT04919473 -
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
Completed |
NCT01205035 -
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
|
Phase 2 | |
Completed |
NCT00812760 -
Effect of Levodopa on Human Multifocal Electroretinogram
|
Phase 4 | |
Active, not recruiting |
NCT06071546 -
Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology
|
N/A | |
Completed |
NCT02946879 -
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
|
||
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Recruiting |
NCT04592068 -
AI Classifies Multi-Retinal Diseases
|
||
Completed |
NCT01746563 -
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01399515 -
Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
|
Phase 2 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT03954626 -
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
|
Phase 3 | |
Completed |
NCT02582164 -
Long-Working Distance OCT for Children
|
N/A | |
Completed |
NCT01790958 -
Microcurrent Stimulation to Treat Macular Degeneration
|
N/A | |
Recruiting |
NCT05283941 -
Pistachios and Neural Macular Pigment
|
N/A | |
Completed |
NCT04678375 -
Artificial Intelligence for Detecting Retinal Diseases
|
||
Completed |
NCT04902170 -
Long-shaft Vitrectomy Probe in Highly Myopic Eyes
|
N/A |